Proteostasis Therapeutics, Inc.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2007-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.proteostasis.com
Clinical Trials
10
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (10 trials with phase data)• Click on a phase to view related trials
Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis
- First Posted Date
- 2018-07-18
- Last Posted Date
- 2020-02-27
- Lead Sponsor
- Proteostasis Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03591094
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
🇺🇸Stanford University, Stanford, California, United States
Safety, Tolerability, and Pharmacokinetics of PTI-808, PTI-801, and PTI-428 Combination Therapy in Subjects With Cystic Fibrosis
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2020-04-06
- Lead Sponsor
- Proteostasis Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03500263
- Locations
- 🇬🇧
Celerion, Belfast, United Kingdom
🇬🇧Western General Hospital, Edinburgh, United Kingdom
🇬🇧Queen Elizabeth University Hospital, Glasgow, United Kingdom
Study Assessing PTI-428 Safety, Tolerability, and Pharmacokinetics in Subjects With Cystic Fibrosis on KALYDECO® as Background Therapy
- First Posted Date
- 2017-08-23
- Last Posted Date
- 2020-03-26
- Lead Sponsor
- Proteostasis Therapeutics, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT03258424
- Locations
- 🇬🇧
Celerion, Belfast, United Kingdom
🇬🇧Medicines Evaluation Unit, Manchester, United Kingdom
Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis
- Conditions
- Cystic Fibrosis - CompleteHealthy Volunteer - Complete
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2020-04-22
- Lead Sponsor
- Proteostasis Therapeutics, Inc.
- Target Recruit Count
- 179
- Registration Number
- NCT03251092
- Locations
- 🇺🇸
Banner University of Arizona Medical Center, Tucson, Arizona, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
🇺🇸National Jewish Health, Denver, Colorado, United States
Study Assessing the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interactions of PTI-801 in Healthy Volunteers, and Safety, Tolerability, and Pharmacokinetics of PTI-801 in Subjects With Cystic Fibrosis
- Conditions
- Healthy VolunteerCystic Fibrosis
- Interventions
- First Posted Date
- 2017-05-04
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Proteostasis Therapeutics, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT03140527
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Providence Alaska Medical Center, Anchorage, Alaska, United States
🇺🇸Stanford University Medical Center, Stanford, California, United States
- Prev
- 1
- 2
- Next